With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset

As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FD | As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate Elahere, another of the acquired company’s clinical assets has crossed the FDA finish line.